About this trial
This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Willing to participate in the study and provide written informed consent
Age ≥18 years at the time of signing informed consent; no sex restriction
Histologically or cytologically confirmed colorectal cancer (CRC)
KRAS G12D mutation confirmed by the central laboratory
Disqualifiers
Other malignancy that has progressed or required treatment within 3 years prior to randomization
Known presence of other actionable/targetable driver gene alterations
Leptomeningeal metastases, spinal cord compression, or active/symptomatic brain metastases
Pleural effusion, ascites, or pericardial effusion requiring repeated puncture/drainage (≥2 times/month) or causing significant symptoms within 28 days prior to randomization
Trial design
Parallel
Treatments tested in this trial
GFH375 + Cetuximab
DrugGFH375:600 mg orally, once daily Cetuximab :500 mg/m² intravenously every 2 weeks
Fruquintinib
Drug35 mg/m² orally twice daily (max single dose 80 mg) on Days 1-5 and Days 8-12
Trifluridine and Tipiracil
Drug5 mg orally once daily on Days 1-21
Treatment groups
Trial outcomes
Primary outcomes
Progression-free survival (PFS)
Progression-free survival (PFS) assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Overall survival(OS)
Overall survival
Secondary outcomes
Progression-free survival (PFS) assessed by the investigator
PFS assessed by the investigator according to RECIST v1.1
Objective response rate (ORR)
Objective response rate (ORR) assessed by BICR and the investigator according to RECIST v1.1
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v6.0
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) leading to treatment modifications
Incidence and severity of AEs/SAEs leading to treatment discontinuation, treatment interruption, and dose reduction
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: